|
1
|
Link MP, Goorin AM, Miser AW, Green AA,
Pratt CB, Belasco JB, et al: The effect of adjuvant chemotherapy on
relapse-free survival in patients with osteosarcoma of the
extremity. N Engl J Med. 314:1600–1606. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fuchs N, Bielack SS, Epler D, Bieling P,
Delling G, Korcholz D, et al: Long-term results of the co-operative
German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86
of intensive multidrug chemotherapy and surgery for osteosarcoma of
the limbs. Ann Oncol. 9:893–899. 1998.PubMed/NCBI
|
|
3
|
Bacci G, Ferrari S, Bertoni F, Ruggieri P,
Picci P, Longhi A, et al: Long-term ourcome for patients with
nonmetastatic osteosarcoma of the extremity treated at the istituto
ortopedico Rizzoli according to the institute orotpedico
Rizzoli/osteosarcoma-2 protocol: an update report. J Clin Oncol.
18:4016–4627. 2000.
|
|
4
|
Bielack S, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, et al: Prognositic factors in
high-grade osteosarcoma of the extremities or trunk: An analysis of
1,702 patients treated on neoadjuvant cooperative osteosarcoma
study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar
|
|
5
|
Smeland S, Müller C, Alvegaard TA, Wiklund
T, Wiebe T, Bjork O, et al: Scandinavian Sarcoma Group Osteosarcoma
study SSG VIII: prognostic factors for outcome and the role of
replacement salvage chemotherapy for poor histological responders.
Eur J Cancer. 39:488–494. 2003. View Article : Google Scholar
|
|
6
|
Ferrari S, Smeland S, Mercuri M, Bertoni
F, Longhi A, Ruggieri P, et al: Neoadjuvant chemotherapy with
high-dose Ifosfamide, high-dose methotrexate, cisplatin, and
doxorubicin for patients with localized osteosarcoma of the
extremity: a joint study by the Italian and Scandinavian sarcoma
groups. J Clin Oncol. 23:8845–8852. 2005. View Article : Google Scholar
|
|
7
|
Ozer H, Armitage JO, Bennett CL, Crawford
J, Demetri GD, Pizzo PA, et al: 2000 update of recommendations for
the use of hematopoietic colony-stimulating factors:
evidence-based, clinical practice guidelines. American Society of
Clinical Oncology Growth Factors Expert Panel. J Clin Oncol.
18:3558–3385. 2000.
|
|
8
|
Rolston KV: New trends in patient
management: risk-based therapy for febrile patients with
neutropenia. Clin Infect Dis. 29:515–521. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonadonna G, Valagussa P, Molitemi A,
Zambetti M and Brambilla C: Adjuvant cyclophosphamide,
methotrexate, and fluorouracil in node-positive breast cancer: the
results of 20 years of follow-up. N Engl J Med. 332:901–906.
1995.PubMed/NCBI
|
|
10
|
Budman DR, Berry DA, Cirrincione CT,
Henderson IC, Wood WC, Weiss RB, et al: Dose and dose intensity as
determinants of outcome in the adjuvant treatment of breast cancer.
The Cancer and Leukemia Group B. J Natl Cancer Inst. 90:1205–1211.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kwak LW, Halpern J, Olshen RA and Horning
SJ: Prognostic significance of actual dose intensity in diffuse
large-cell lymphoma: results of a tree-structured survival
analysis. J Clin Oncol. 8:963–977. 1990.PubMed/NCBI
|
|
12
|
Talcott JA, Siegel RD, Finberg R and
Goldman L: Risk assessment in cancer patients with fever and
neutropenia: A prospective two center validation of a prediction
rule. J Clin Oncol. 10:316–322. 1992.PubMed/NCBI
|
|
13
|
Blay JY, Chauvin F, Le Cesne A, Anglaret
B, Bouhour D, Lasset C, et al: Early lymphopenia after cytotoxic
chemotherapy as a risk factor for febrile neutropenia. J Clin
Oncol. 14:636–643. 1996.PubMed/NCBI
|
|
14
|
Coiffier B, Gisselbrecht C, Herbercht R,
Tilly H, Bosly A and Brousse N: LNH-84 regimen: a multicenter study
of intensive chemotherapy in 737 patients with aggressive malignant
lymphoma. J Clin Oncol. 7:1018–1026. 1989.PubMed/NCBI
|
|
15
|
Dale DC, McCarter GC, Crawford J and Lyman
GH: Myelotoxicity and dose intensity of chemotherapy: reporting
practices from randomized clinical trials. J Natl Compr Canc Netw.
1:440–454. 2003.PubMed/NCBI
|
|
16
|
Kloess M, Wunderlich A and Trumper L:
Predicting hematotoxicity in multicycle chemotherapy. Blood.
94(Suppl 1): 87a1999.
|
|
17
|
Lyman GH, Morrison VA, Dale DC, Crawford
J, Delgado DJ, Fridman M, et al: Risk of febrile neutropenia among
patients with intermediate-grade non-Hodgkin’s lymphoma receiving
CHOP chemotherapy. Leuk Lymphoma. 44:2069–2076. 2003.
|
|
18
|
Morrison VA, Picozzi V, Scott S, Pohlman
B, Dickman E, Lee M, et al: The impact of age on delivered dose
intensity and hospitalizations for febrile neutropenia in patients
with intermediate-grade non-Hodgkin’s lymphoma receiving initial
CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2:47–56.
2001.PubMed/NCBI
|
|
19
|
Lyman GH, Dale DC, Friedberg J, Crawford J
and Fisher RI: Incidence and predictors of low chemotherapy
dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide
study. J Clin Oncol. 22:4302–4311. 2004.PubMed/NCBI
|
|
20
|
Morrison VA, Caggiano V, Fridman M, Dale
DC, Crawford J, Delagado DJ, et al: A model to predict
chemotherapy-related severe or febrile neutropenia in cycle one
among breast cancer and lymphoma patients. Proc Am Soc Clin Oncol.
23:7422004.
|
|
21
|
Aslani A, Smith RC, Allen BJ, Pavlakis N
and Levi JA: The predictive value of body protein for
chemotherapy-induced toxicity. Cancer. 88:796–803. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lyman GH, Dale DC and Crawford J:
Incidence and predictors of low dose-intensity in adjuvant breast
cancer chemotherapy: a nationwide study of community practices. J
Clin Oncol. 21:4524–4531. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klastersky J, Paesmans M, Rubenstein EB,
Boyer M, Elting L, Feld R, et al: The multinational association for
supportive care in cancer risk index: a multinational scoring
system for identifying low-risk febrile neutropenic cancer
patients. J Clin Oncol. 18:3038–3051. 2000.PubMed/NCBI
|
|
24
|
Kuderer NM, Dale DC, Crawford J, Cosler LE
and Lyman GH: Mortality, morbidity, and cost associated with
febrile neutropenia in adult cancer patients. Cancer.
106:2258–2266. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim YJ, Rubenstein EB and Rolston KV:
Colony stimulating factors (CSFs) may reduce complications and
death in solid tumor patients (Pts) with fever and neutropenia.
Proc Am Soc Clin Oncol. 19:612a2000.
|
|
26
|
Voog E, Bienvenu J, Warzocha K, Moullet I,
Dumontet C, Thieblemont C, et al: Factors that predict
chemotherapy-induced myelosuppression in lymphoma patients: role of
the tumor necrosis factor ligand-receptor system. J Clin Oncol.
18:325–331. 2000.PubMed/NCBI
|
|
27
|
Silber JH, Fridman M, DiPaola RS, Erder
MH, Pauly MV and Fox KR: First-cycle blood counts and subsequent
neutropenia, dose reduction, or delay in early-stage breast cancer
therapy. J Clin Oncol. 16:2392–2400. 1998.PubMed/NCBI
|
|
28
|
Bladucci L and Extermann M: Cancer and
aging. An evolving panorama. Hematol Oncol Clin North Am. 14:1–16.
2000. View Article : Google Scholar
|
|
29
|
Cvitkovic E: Cumulative toxicity from
cisplatin therapy and current cytoprotective measures. Cancer Treat
Rev. 24:265–281. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blay JY, Chauvin F, Le Cesne A, Anglaret
B, Bouhour D, Lasset C, et al: Early lymphopenia after cytotoxic
chemotherapy as a risk factor for febrile neutropenia. J Clin
Oncol. 14:636–643. 1996.PubMed/NCBI
|
|
31
|
Voog E, Bienvenu J, Warzocha K, Moullet I,
Dumontet C, Thieblemont C, et al: Factors that predict
chemotherapy-induced myelosuppression in lymphoma patients: role of
the tumor necrosis factor ligand-receptor system. J Clin Oncol.
18:325–331. 2000.PubMed/NCBI
|
|
32
|
Szucs TD, Leonard R and Pettengell R:
Dose-limiting effects of neutropenic events in six European audits
of adjuvant breast cancer chemotherapy. Proc Am Soc Clin Oncol.
24:312004.
|
|
33
|
Rosen G, Caparros B, Huvos AG, Kosloff C,
Nirenberg A, Cacavio A, et al: Preoperative chemotherapy for
osteogenic sarcoma: selection of postoperative adjuvant
chemotherapy based on the response of the primary tumor to
preoperative chemotherapy. Cancer. 15:1221–1230. 1982. View Article : Google Scholar
|
|
34
|
Offinger KC and Hudson MM: Long term
complications following childhood and adolescent cancer:
foundations for providing Risk-based health care for survivors. CA
Cancer J Clin. 54:208–236. 2004. View Article : Google Scholar : PubMed/NCBI
|
